Mar 5, 2026
There has been a lot of discussion about Category H at recent events, online and on socials. Charles Joynson, WaveData MD, poses the question; ‘Will it cut another group of generics to the bone and seriously damage pharmacy and supplier profitability? Or will it...
Feb 16, 2026
We know that pharmacies buying generics are making a loss when they dispense. Previous analysis, available on the Wavedata.co.uk articles page, shows that over 1200 generic products each month are unprofitable. However, what about parallel imports, are they profitable...
Feb 13, 2026
Charles Joynson, WaveData MD, was delighted to join Jeremy Durrant, Director of Communications and External Engagement at Medicines UK, in the latest episode of their podcast Medicine Matters. It’s a lively discussion, looking at pricing trends over the last 12...
Sep 16, 2025
Leslie Galloway, EMIG Chairman, shared his analysis of VPAG. Here’s Charles’ key takeaways: · The NHS VPAG rebate is £1bn over 3 years and so is a fixed rebate with risk share. · Global Pharma CEOs have asked for lower rebates and a better deal, that...
Sep 16, 2025
Charles Joynson, WaveData MD, decided to have a look at the differences between the average market price for generics and the English drug tariff. He wanted to know if the gap between the two was being squeezed, resulting in some of the misery pharmacists are going...
Sep 11, 2025
Isotrex Gel 0.05% was first launched in the UK by Stiefel Laboratories Ltd on 10 November 2002. It was primarily used to treat acne vulgaris in adolescents and contained isotretinoin, a compound similar to Vitamin A. The first parallel import appeared in the UK in...
